August 30, 2018
AstraZeneca’s anti-PD-L1 antibody Imfinzi (durvalumab) and Chugai Pharmaceutical’s cancer treatment Gazyva (obinutuzumab) hit the Japan market on August 29 upon their NHI price listing the same day. Imfinzi picked up Japanese approval in July this year as maintenance therapy after...read more